These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31489538)

  • 21. Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis.
    Ungar B; Mazor Y; Weisshof R; Yanai H; Ron Y; Goren I; Waizbard A; Yavzori M; Fudim E; Picard O; Loebstein R; Kopylov U; Dotan I; Chowers Y; Eliakim R; Ben-Horin S
    Aliment Pharmacol Ther; 2016 Jun; 43(12):1293-9. PubMed ID: 27091119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date.
    Thukral C; Cheifetz A; Peppercorn MA
    Drugs; 2006; 66(16):2059-65. PubMed ID: 17112300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Compassionate access anti-tumour necrosis factor-α therapy for ulcerative colitis in Australia: the benefits to patients.
    Costello SP; Ghaly S; Beswick L; Pudipeddi A; Agarwal A; Sechi A; O'Connor S; Connor SJ; Sparrow MP; Bampton P; Walsh AJ; Andrews JM;
    Intern Med J; 2015 Jun; 45(6):659-66. PubMed ID: 25732268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Golimumab for the treatment of ulcerative colitis.
    Flamant M; Paul S; Roblin X
    Expert Opin Biol Ther; 2017 Jul; 17(7):879-886. PubMed ID: 28472597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model.
    Ternant D; Le Tilly O; Picon L; Moussata D; Passot C; Bejan-Angoulvant T; Desvignes C; Mulleman D; Goupille P; Paintaud G
    Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study.
    Naviglio S; Lacorte D; Lucafò M; Cifù A; Favretto D; Cuzzoni E; Silvestri T; Pozzi Mucelli M; Radillo O; Decorti G; Fabris M; Bramuzzo M; Taddio A; Stocco G; Alvisi P; Ventura A; Martelossi S
    J Pediatr Gastroenterol Nutr; 2019 Jan; 68(1):37-44. PubMed ID: 30211845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis.
    Olsen T; Cui G; Goll R; Husebekk A; Florholmen J
    Scand J Gastroenterol; 2009; 44(6):727-35. PubMed ID: 19294580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.
    Fasanmade AA; Adedokun OJ; Olson A; Strauss R; Davis HM
    Int J Clin Pharmacol Ther; 2010 May; 48(5):297-308. PubMed ID: 20420786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis.
    Wei X; Gibiansky L; Wang Y; Fuh F; Erickson R; O'Byrne S; Tang MT
    J Clin Pharmacol; 2018 Mar; 58(3):386-398. PubMed ID: 29178491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling.
    Kimura K; Yoshida A; Katagiri F; Takayanagi R; Yamada Y
    Biopharm Drug Dispos; 2019 Jul; 40(7):250-261. PubMed ID: 31256430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ulcerative Colitis-associated Spondyloarthritis Successfully Treated with Infliximab in the Absence of Enhanced TNF-α Responses.
    Fujita S; Honjo H; Takada R; Hara A; Masuta Y; Otsuka Y; Handa K; Minaga K; Tsuji S; Kudo M; Watanabe T
    Intern Med; 2023 Sep; 62(17):2493-2497. PubMed ID: 36575020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of linear IgA bullous disease with ulcerative colitis: a case of successful treatment with infliximab.
    Yamada S; Makino T; Jinnin M; Sakai K; Fukushima S; Inoue Y; Ihn H
    Dermatology; 2013; 227(4):295-8. PubMed ID: 24281360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
    Papamichael K; Rivals-Lerebours O; Billiet T; Vande Casteele N; Gils A; Ferrante M; Van Assche G; Rutgeerts PJ; Mantzaris GJ; Peyrin-Biroulet L; Vermeire S
    J Crohns Colitis; 2016 Sep; 10(9):1015-23. PubMed ID: 27022161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study.
    Adedokun OJ; Xu Z; Padgett L; Blank M; Johanns J; Griffiths A; Ford J; Zhou H; Guzzo C; Davis HM; Hyams J
    Inflamm Bowel Dis; 2013 Dec; 19(13):2753-62. PubMed ID: 24193155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis.
    Vande Casteele N; Jeyarajah J; Jairath V; Feagan BG; Sandborn WJ
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1814-1821.e1. PubMed ID: 30613004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infliximab inhibits activation and effector functions of peripheral blood T cells in vitro from patients with clinically active ulcerative colitis.
    Dahlén R; Strid H; Lundgren A; Isaksson S; Raghavan S; Magnusson MK; Simrén M; Sjövall H; Öhman L
    Scand J Immunol; 2013 Sep; 78(3):275-84. PubMed ID: 23713660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
    Lawson MM; Thomas AG; Akobeng AK
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China.
    Zhou YL; Xie S; Wang P; Zhang T; Lin MY; Tan JS; Zhi FC; Jiang B; Chen Y
    J Dig Dis; 2014 Sep; 15(9):483-90. PubMed ID: 24828856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.